Helmy Eltoukhy

Helmy Eltoukhy is a prominent scientist, entrepreneur, and business leader in the biotech industry. He currently serves as a Member of the Board of Directors at Paradromics Inc., a company developing brain-computer interface technology.4

Professional Background

Eltoukhy is best known as the co-founder, Chairman, and co-CEO of Guardant Health, a precision oncology company he established in 2012.12 Under his leadership, Guardant Health has made significant advancements in liquid biopsy technology, including the development of comprehensive liquid biopsies for advanced-stage cancer patients and blood-only tests for cancer recurrence monitoring.2

Education and Early Career

Helmy Eltoukhy received his Ph.D., M.S., and B.S. degrees in electrical engineering from Stanford University.1 During his doctoral studies and post-doctoral work at the Stanford Genome Technology Center, he developed pioneering technologies in DNA sequencing, including the first semiconductor sequencing platform.1

Other Roles and Achievements

Entrepreneurial Ventures::

• Co-founded Avantome Inc. in 2007, which was later acquired by Illumina1
• Held various positions at Illumina, including Senior Director of Advanced Technology Research1

Board Memberships::

• Serves on the boards of SETI (Search for Extraterrestrial Intelligence), the Personalized Medicine Coalition, and Paradromics2

Investment::

• Partner at Green Sands Equity24

Honors and Recognition

Eltoukhy has received numerous accolades for his contributions to healthcare and technology:

• Named to Time Magazine's inaugural 50 Most Influential People in Healthcare23
• Included in Fortune's 40 under 40 list3
• Recognized as a World Economic Forum Technology Pioneer3

Expertise and Impact

Helmy Eltoukhy is renowned for his contributions to next-generation DNA sequencing and non-invasive liquid biopsy technologies.2 He has co-authored influential publications in the sequencing and cancer fields and is a co-inventor on over 50 issued US patents.2